- Apax’s investment will help Porsolt grow further and implement its strategy to become a ‘comprehensive’ preclinical service company
- Apax is a private equity firm headquartered in Paris, France
- It manages funds more than €5 billion
Apax Partners sas has acquired a majority stake in Porsolt, a global preclinical Contract Research Organisation (CRO). No financial details of the transaction were disclosed.
Porsolt is based in Le Genest-Saint-Isle, France.
“We are excited about our new investment, as we see Porsolt as a significant player in the preclinical service space,“ said Stanislas Panhard, partner at Apax Development. “We look forward to supporting the team and contributing our expertise where needed, in order to help Porsolt move to the next level in particular through bolt-on acquisitions in Europe and in the US, and become a key industry leader.”
Apax’s investment will accelerate Porsolt’s growth and assist in implementing its strategy to become a comprehensive preclinical service company, according to a release.
Additionally, this will strengthen Porsolt’s current service offering, while also expanding its portfolio and capabilities for drug screening, efficacy, and safety, the release stated.
Apax is a private equity firm headquartered in Paris, France. It manages more than €5 billion. The firm invests in high-growth SMEs and SMIs in technology and telecom, services, health and consumer goods.